Autolus Therapeutics (AUTL) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed ProKidney (PROK) over the past year, gaining 21.5% versus a loss of 47.0%. Over five years, AUTL leads with a -70.5% price change compared with -84.1% for PROK. ProKidney is the larger company by market cap ($652.7 million vs $467.1 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | PROK |
|---|---|---|
| Share price | $1.76 | $1.64 |
| Market cap | $467.12M | $652.66M |
| 1-day change | -3.04% | +4.14% |
| YTD return | -9.05% | -29.91% |
| 1-year return | +21.48% | -46.96% |
| 5-year return | -70.52% | -84.09% |
| EPS (TTM) | $-1.06 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $3.48 |
| 52-week low | $1.18 | $1.30 |
| Distance from 52-week high | -31.98% | -53.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +397.44% | +282.26% |
| Average volume | 2.10M | 1.30M |
| Shares outstanding | 266.16M | 208.93M |
| Employees | 752 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed PROK by 68.4 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
AUTL vs PROK FAQ
Which is bigger, Autolus Therapeutics or ProKidney?
ProKidney (PROK) is larger, with a market capitalization of $652.66M compared with $467.12M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, AUTL or PROK?
AUTL returned +21.48% over the past 12 months, compared with -46.96% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.